Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
aforementioned, appeal, ballot, blood, Canadian, CDPA, Colorado, combat, Connecticut, constitutionality, CPA, CPDA, CPRA, CTDPA, depth, dismissed, empyema, enLIGHTEN, excessive, gcomprehensive, glioblastoma, globe, gouging, governor, Indian, instructed, Lamont, lawsuit, Maryland, median, methylated, MGMT, Modernization, moratorium, motion, nivolumab, nomenclature, oral, paired, pyrexia, radiotherapy, randomized, ratio, regime, regression, sixty, stay, suggesting, temozolomide, UCPA, UK, unnecessary, Utah, variation, Virginia, waiver, whichever, wproduct
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view